246 related articles for article (PubMed ID: 21829023)
1. Future treatment option for hepatocellular carcinoma: a focus on brivanib.
Kudo M
Dig Dis; 2011; 29(3):316-20. PubMed ID: 21829023
[TBL] [Abstract][Full Text] [Related]
2. Positioning of a molecular-targeted agent, sorafenib, in the treatment algorithm for hepatocellular carcinoma and implication of many complete remission cases in Japan.
Kudo M; Ueshima K
Oncology; 2010 Jul; 78 Suppl 1():154-66. PubMed ID: 20616599
[TBL] [Abstract][Full Text] [Related]
3. Brivanib as adjuvant therapy to transarterial chemoembolization in patients with hepatocellular carcinoma: A randomized phase III trial.
Kudo M; Han G; Finn RS; Poon RT; Blanc JF; Yan L; Yang J; Lu L; Tak WY; Yu X; Lee JH; Lin SM; Wu C; Tanwandee T; Shao G; Walters IB; Dela Cruz C; Poulart V; Wang JH
Hepatology; 2014 Nov; 60(5):1697-707. PubMed ID: 24996197
[TBL] [Abstract][Full Text] [Related]
4. Brivanib alaninate, a dual inhibitor of vascular endothelial growth factor receptor and fibroblast growth factor receptor tyrosine kinases, induces growth inhibition in mouse models of human hepatocellular carcinoma.
Huynh H; Ngo VC; Fargnoli J; Ayers M; Soo KC; Koong HN; Thng CH; Ong HS; Chung A; Chow P; Pollock P; Byron S; Tran E
Clin Cancer Res; 2008 Oct; 14(19):6146-53. PubMed ID: 18829493
[TBL] [Abstract][Full Text] [Related]
5. Brivanib in patients with advanced hepatocellular carcinoma who were intolerant to sorafenib or for whom sorafenib failed: results from the randomized phase III BRISK-PS study.
Llovet JM; Decaens T; Raoul JL; Boucher E; Kudo M; Chang C; Kang YK; Assenat E; Lim HY; Boige V; Mathurin P; Fartoux L; Lin DY; Bruix J; Poon RT; Sherman M; Blanc JF; Finn RS; Tak WY; Chao Y; Ezzeddine R; Liu D; Walters I; Park JW
J Clin Oncol; 2013 Oct; 31(28):3509-16. PubMed ID: 23980090
[TBL] [Abstract][Full Text] [Related]
6. Phase II, open-label study of brivanib as second-line therapy in patients with advanced hepatocellular carcinoma.
Finn RS; Kang YK; Mulcahy M; Polite BN; Lim HY; Walters I; Baudelet C; Manekas D; Park JW
Clin Cancer Res; 2012 Apr; 18(7):2090-8. PubMed ID: 22238246
[TBL] [Abstract][Full Text] [Related]
7. Brivanib versus sorafenib as first-line therapy in patients with unresectable, advanced hepatocellular carcinoma: results from the randomized phase III BRISK-FL study.
Johnson PJ; Qin S; Park JW; Poon RT; Raoul JL; Philip PA; Hsu CH; Hu TH; Heo J; Xu J; Lu L; Chao Y; Boucher E; Han KH; Paik SW; Robles-Aviña J; Kudo M; Yan L; Sobhonslidsuk A; Komov D; Decaens T; Tak WY; Jeng LB; Liu D; Ezzeddine R; Walters I; Cheng AL
J Clin Oncol; 2013 Oct; 31(28):3517-24. PubMed ID: 23980084
[TBL] [Abstract][Full Text] [Related]
8. Complete remission of hepatocellular carcinoma after transarterial Chemoembolization combined with brivanib.
Jia J; Qi X; Bai W; Yuan J; Han G
J Cancer Res Ther; 2014; 10(4):1112-4. PubMed ID: 25579566
[TBL] [Abstract][Full Text] [Related]
9. Molecularly targeted therapies for hepatocellular carcinoma: sorafenib as a stepping stone.
Kim HY; Park JW
Dig Dis; 2011; 29(3):303-9. PubMed ID: 21829021
[TBL] [Abstract][Full Text] [Related]
10. Signaling pathway and molecular-targeted therapy for hepatocellular carcinoma.
Kudo M
Dig Dis; 2011; 29(3):289-302. PubMed ID: 21829020
[TBL] [Abstract][Full Text] [Related]
11. Hepatocellular carcinoma 2009 and beyond: from the surveillance to molecular targeted therapy.
Kudo M
Oncology; 2008; 75 Suppl 1():1-12. PubMed ID: 19092266
[TBL] [Abstract][Full Text] [Related]
12. The effects of liver impairment on the pharmacokinetics of brivanib, a dual inhibitor of fibroblast growth factor receptor and vascular endothelial growth factor receptor tyrosine kinases.
El-Khoueiry A; Posey JA; Castillo Ferrando JR; Krishnamurthi SS; Syed S; Kollia G; Walters I; Fischer BS; Masson E
Cancer Chemother Pharmacol; 2013 Jul; 72(1):53-64. PubMed ID: 23719718
[TBL] [Abstract][Full Text] [Related]
13. Phase II, open-label study of brivanib as first-line therapy in patients with advanced hepatocellular carcinoma.
Park JW; Finn RS; Kim JS; Karwal M; Li RK; Ismail F; Thomas M; Harris R; Baudelet C; Walters I; Raoul JL
Clin Cancer Res; 2011 Apr; 17(7):1973-83. PubMed ID: 21349999
[TBL] [Abstract][Full Text] [Related]
14. Positioning and indication of sorafenib in the treatment algorithm and real practice setting: Western and eastern approach--Asian perspective.
Lee JM; Han KH
Oncology; 2010 Jul; 78 Suppl 1():167-71. PubMed ID: 20616600
[TBL] [Abstract][Full Text] [Related]
15. Molecular targeted therapy for hepatocellular carcinoma: bench to bedside.
Kudo M
Dig Dis; 2011; 29(3):273-7. PubMed ID: 21829017
[TBL] [Abstract][Full Text] [Related]
16. Growth factors as therapeutic targets in HCC.
Furuse J
Crit Rev Oncol Hematol; 2008 Jul; 67(1):8-15. PubMed ID: 18434184
[TBL] [Abstract][Full Text] [Related]
17. Molecular pathogenesis and targeted therapy of hepatocellular carcinoma.
Zender L; Kubicka S
Onkologie; 2008 Oct; 31(10):550-5. PubMed ID: 18854656
[TBL] [Abstract][Full Text] [Related]
18. Angiogenesis and antiangiogenic therapy in hepatocellular carcinoma.
Pang R; Poon RT
Cancer Lett; 2006 Oct; 242(2):151-67. PubMed ID: 16564617
[TBL] [Abstract][Full Text] [Related]
19. Treatment of intermediate/advanced hepatocellular carcinoma in the clinic: how can outcomes be improved?
Lencioni R; Chen XP; Dagher L; Venook AP
Oncologist; 2010; 15 Suppl 4():42-52. PubMed ID: 21115580
[TBL] [Abstract][Full Text] [Related]
20. Asian consensus workshop report: expert consensus guideline for the management of intermediate and advanced hepatocellular carcinoma in Asia.
Han KH; Kudo M; Ye SL; Choi JY; Poon RT; Seong J; Park JW; Ichida T; Chung JW; Chow P; Cheng AL
Oncology; 2011; 81 Suppl 1():158-64. PubMed ID: 22212951
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
